Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer

Article ID	Journal	Published Year	Pages	File Type
10103907	Journal of the American College of Surgeons	2005	9 Pages	PDF

Abstract

The expression levels of a set of genes that are possible determinants of 5-FU/cisplatin/radiation therapy antitumor activity are significantly downregulated by neoadjuvant radiochemotherapy in esophageal cancer.

Keywords

EGFR HER2 qRT-PCR GST-pi CDDP DPD dihydropyrimidine dehydrogenase thymidylate synthase cisplatin map quantitative reverse transcription polymerase chain reaction mitogen-activated protein kinase ERCC1 Human epidermal growth factor receptor 2 Epidermal growth factor receptor

Related Topics

Health Sciences Medicine and Dentistry Surgery

Preview

Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer

Authors

Sylke MD, Kazumi MD, Jan MD, Stephan E. MD, JiMin PhD, Kathleen D. BS, Dennis MS, Pei MD, Denice MS, Susan PhD, Arnulf H. MD, Paul M. MD, Peter V. PhD,